Hair loss and brow thinning sit at the intersection of dermatology and self-image — among the most requested concerns in aesthetic consultations, yet served by a narrow set of established pharmacological options.
Recent research attention has shifted from the follicle alone to the follicle niche: the signalling environment, growth-cycle regulation and surrounding scalp biology that together determine density, calibre and resilience.
For pharmaceutical developers, this opens differentiated program design — from direct follicle bio-stimulation to microenvironment support and post-procedural adjunct care.
ObNowa Pharma's hair-growth programs, built on science originating from Aneira Pharma, span two clinical-development programs across these mechanisms, covering pattern hair loss and eyebrow density. All remain investigational.
This article is for informational purposes and does not describe approved products or established clinical efficacy.
Development status — all programs presented are currently in research and development. Potential indications and applications reflect development objectives and do not represent established efficacy, safety or regulatory approval.